Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

The ctl epitope of hepatitis B virus core antigen and its related application

A hepatitis B virus and epitope peptide technology, applied in the direction of viruses, viral peptides, viruses/phages, etc., can solve problems such as inability to cure hepatitis B or other complications, and inability to effectively block liver fibrosis and sclerosis. Fibrosis and sclerosis, improvement of clinical symptoms

Active Publication Date: 2017-05-03
海图生物科技(上海)有限责任公司 +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most of the prior art uses traditional Chinese medicine or western medicine to treat hepatitis B. Although it has a certain effect, it cannot cure hepatitis B or other complications, especially it cannot effectively block liver fibrosis and cirrhosis caused by hepatitis B virus infection, and block the passage of hepatitis B virus. The placenta transmits to the fetus and blocks the transmission of hepatitis B virus to breastfed newborns through milk

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • The ctl epitope of hepatitis B virus core antigen and its related application
  • The ctl epitope of hepatitis B virus core antigen and its related application
  • The ctl epitope of hepatitis B virus core antigen and its related application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Example 1 Study on Antiviral Activity of Dendritic Cells Loaded with Epitope Peptides

[0017] Preparation of epitope peptide-loaded dendritic cells: extract mouse femoral bone marrow cells under sterile conditions, put them into PRMI1640 culture medium (containing 10% fetal bovine serum, 0.1ml penicillin-streptomycin) and mix well by pipetting for 3 hours Then take the adherent cells and add IL-4 (final concentration is 500U / ml) and GM-CSF (final concentration is 1000U / ml), at 37°C, 5% CO 2 cultured in an incubator. Half of the medium was replaced every 3 days, and GM-CSF and IL-4 were added at the same time to induce the generation of dendritic cells. After culturing for 10 days, add a final concentration of 0.1mg / L epitope peptide and 1×10 6 Dendritic cells per L were co-incubated at 37°C for 24 hours, and the activated dendritic cells were collected.

[0018] Female HBV transgenic Babl / c mice aged 6-8 weeks were randomly divided into experimental group, control g...

Embodiment 2

[0026] Example 2 Antiviral Clinical Research of Dendritic Cells Loaded with Epitope Peptides

[0027] Clinically collected 200 patients who were HBeAg positive and had not received antiviral or immunomodulatory drug treatment for 6 months before administration. After testing, its HBV-DNA≥1000copies / mL (ALT≥40IU, ALT<40IU).

[0028] Preparation of dendritic cells loaded with epitope peptides: The peripheral blood mononuclear cells of the patient were isolated by leukapheresis, and the purity of CD14+ cells was up to 94%. After being treated with GM-CSF and IL-4, the cells became obvious dendrites. On the 10th day of culture, most of the cells expressed co-stimulatory molecule markers CD86, CD40, CD80 and HLA-DR, MHC-I molecules. Immediately add the epitope peptide of final concentration 0.1mg / L (epitope peptide sequence is with embodiment 1) and 1 * 10 6 Dendritic cells / L were co-incubated at 37°C for 24 hours, and the activated dendritic cells were collected.

[0029] Intra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of biological medicine, in particular to hepatitis B virus T epitope peptide which can be used for effectively treating hepatitis B and various complications, and cutting off placental infection to a fetus and milk-born infection of hepatitis B virus to a new born child, and is based on DC cells. The amino acid sequence of the T epitope peptide is QLFHLZLIX (glutamine-leucine-phenylalanine-histidine-leucine-Z-leucine-isoleucine-X), wherein X and Z are optional amino acids.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the CTL epitope of the core antigen of hepatitis B virus and related applications thereof. Background technique [0002] Worldwide, more than 400 million people are infected with the hepatitis B virus, and 1 million people die each year from complications of the infection, including cirrhosis, hepatocellular carcinoma, or other complications. Most of the prior art uses traditional Chinese medicine or western medicine to treat hepatitis B. Although it has a certain effect, it cannot cure hepatitis B or other complications, especially it cannot effectively block liver fibrosis and cirrhosis caused by hepatitis B virus infection, and block the passage of hepatitis B virus. The placenta is transmitted to the fetus, and the transmission of hepatitis B virus to breast-fed newborns through milk is blocked. [0003] Peptide synthesis technology is currently carried out in some institutions at...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/02C12N5/0784
CPCC07K14/005C12N5/0639C12N2501/22C12N2501/2304C12N2506/115C12N2730/10122
Inventor 阎平希罗进闫小君
Owner 海图生物科技(上海)有限责任公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com